**Table S1.** Change in efficacy and patient-reported outcomes 4, 8, and 12 weeks after rescue in patients who were initially randomized to placebo and rescued to baricitinib in RA-BEAM between weeks 16 and 24

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Placebo to Baricitinib (N=128)** | | | |
|  | **Score at Time of Rescue** | **Change From Rescue Visit** | | |
|  | **Week 4 (n=128)** | **Week 8 (n=126)** | **Week 12 (n=103)** |
| DAS28-ESR | 6.4 (1.1) | -1.53 (0.1)\*\*\* | -2.05 (0.10)\*\*\* | -2.35 (0.12)\*\*\* |
| CDAI | 37.4 (13.2) | -16.3 (1.1)\*\*\* | -21.83 (1.1)\*\*\* | -23.5 (1.2)\*\*\* |
| SDAI | 40.1 (14.4) | -18.2 (1.2)\*\*\* | -24.0 (1.2)\*\*\* | -25.5 (1.3)\*\*\* |
| Patient’s assessment of pain | 56.8 (24.1) | -23.7 (2.0)\*\*\* | -26.6 (2.0)\*\*\* | -29.3 (2.1)\*\*\* |
| HAQ-DI | 1.48 (0.70) | -0.39 (0.04)\*\*\* | -0.50 (0.04)\*\*\* | -0.55 (0.05)\*\*\* |

CDAI, Clinical Disease Activity Index; DAS28-ESR, Disease Activity Score using 28 joint count with erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; LSM, least squares mean; MMRM, mixed effects model repeated measures; SDAI, Simplified Disease Activity Index.

Score at time of rescue data are mean (SD); change from baseline data are LSM (SE).

\*p≤0.05, \*\*p≤0.01, \*\*\*p≤0.001 from within-group mean change from the last visit prior to rescue using MMRM.